LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)
Rxsight, Inc. · Decision date Nov 22, 2017
What did the FDA approve?
FDA records P160055 as an original PMA application. The recorded decision is approval, dated Nov 22, 2017.
FDA approval order statement
Approval for The Light Adjustable Lens and Light Delivery Device system is indicated for the reduction residual astigmatism to improve uncorrected visual acuity after removal of the cataractous natural lens by phacoemulsification and implantation of the intraocular lens in the capsular bag, in adult patients: 1) With pre-existing corneal astigmatism of => 0.75 diopters; and 2) Without pre-existing macular disease. The system also reduces the likelihood of clinically significant residual spherical refractive errors.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Nov 22, 2017
Regulatory record facts
- Identifier
- P160055
- Regulatory pathway
- Premarket approval application
- Applicant
- Rxsight, Inc.
- Product code
- PZK
- Decision code
- APPR
- Decision date
- Nov 22, 2017
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Light adjustable lens (LAL) and light delivery device (LDD).
- Applicant
- Rxsight, Inc.
- Product code
- PZK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P160055 received
Application receipt date recorded by FDA.
P160055 · FDA decision
APPR
P160055/S056 · Related supplement
RxSight Light Adjustable Lens and Light Delivery Device
P160055/S058 · Related supplement
RxSight Light Adjustable Lens and Light Delivery Device
P160055/S057 · Related supplement
RxSight Light Adjustable Lens and Light Delivery Device
Timeline entries are records held by MedtechLedger for P160055. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160055
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Rxsight, Inc. | PMA supplement | Sep 3, 2026 | FDA | |
| Rxsight, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
| Rxsight, Inc. | PMA supplement | Nov 5, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Rxsight, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 100 Columbia, Aliso Viejo, CA, 92656
Sources and methodology
- Original FDA record: P160055
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

